|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 235/14 | (2006.01) |
| A61P 35/02 | (2006.01) | ||
| A61K 31/4184 | (2006.01) |
| (11) | Patento numeris | 3452035 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17793075.7 |
| Europos patento paraiškos padavimo data | 2017-05-01 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-03-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-07-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2017/030414 |
| Data | 2017-05-01 |
| (87) | Numeris | WO 2017/192451 |
| Data | 2017-11-09 |
| (30) | Numeris | Data | Šalis |
| 201662330673 P | 2016-05-02 | US |
| (72) |
DUNCAN, David , US
|
| (73) |
MEI Pharma, Inc. ,
11455 El Camino Real, Suite 250, San Diego, CA 92130,
US
|
| (54) | POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |
| POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |